These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 36472472)

  • 41. Therapeutic Antibodies in Cancer Treatment in the UK.
    Eltarhoni K; Kamel F; Ihebunezie K; Nisar P; Soloviev M
    Int J Mol Sci; 2022 Nov; 23(23):. PubMed ID: 36498915
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cilgavimab/Tixagevimab as alternative therapeutic approach for BA.2 infections.
    Dichtl S; Zaderer V; Kozubowski V; Abd El Halim H; Lafon E; Lanser L; Weiss G; Lass-Flörl C; Wilflingseder D; Posch W
    Front Med (Lausanne); 2022; 9():1005589. PubMed ID: 36250084
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Safety, pharmacokinetics, and antitumor activity of the anti-CEACAM5-DM4 antibody-drug conjugate tusamitamab ravtansine (SAR408701) in patients with advanced solid tumors: first-in-human dose-escalation study.
    Gazzah A; Bedard PL; Hierro C; Kang YK; Abdul Razak A; Ryu MH; Demers B; Fagniez N; Henry C; Hospitel M; Soria JC; Tabernero J
    Ann Oncol; 2022 Apr; 33(4):416-425. PubMed ID: 35026412
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The global landscape of approved antibody therapies.
    Lyu X; Zhao Q; Hui J; Wang T; Lin M; Wang K; Zhang J; Shentu J; Dalby PA; Zhang H; Liu B
    Antib Ther; 2022 Oct; 5(4):233-257. PubMed ID: 36213257
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Metrics for antibody therapeutics development.
    Reichert JM
    MAbs; 2010; 2(6):695-700. PubMed ID: 20930555
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cancer therapy with bispecific antibodies: Clinical experience.
    Thakur A; Lum LG
    Curr Opin Mol Ther; 2010 Jun; 12(3):340-9. PubMed ID: 20521223
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Fine-tuning bispecific therapeutics.
    Lim SI
    Pharmacol Ther; 2020 Aug; 212():107582. PubMed ID: 32450189
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Bispecific antibody derivatives based on full-length IgG formats.
    Grote M; Haas AK; Klein C; Schaefer W; Brinkmann U
    Methods Mol Biol; 2012; 901():247-63. PubMed ID: 22723106
    [TBL] [Abstract][Full Text] [Related]  

  • 49. World Bispecific Antibody Summit, September 27-28, 2011, Boston, MA.
    Dhimolea E; Reichert JM
    MAbs; 2012; 4(1):4-13. PubMed ID: 22327426
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Generation of dual-variable-domain immunoglobulin molecules for dual-specific targeting.
    Gu J; Ghayur T
    Methods Enzymol; 2012; 502():25-41. PubMed ID: 22208980
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Engineering therapeutic bispecific antibodies using CrossMab technology.
    Klein C; Schaefer W; Regula JT; Dumontet C; Brinkmann U; Bacac M; Umaña P
    Methods; 2019 Feb; 154():21-31. PubMed ID: 30453028
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Teclistamab-cqyv (Tecvayli) for multiple myeloma.
    Med Lett Drugs Ther; 2022 Nov; 64(1663):e196-e197. PubMed ID: 36384770
    [No Abstract]   [Full Text] [Related]  

  • 53. Bispecific antibodies for cancer therapy.
    Hollander N
    Immunotherapy; 2009 Mar; 1(2):211-22. PubMed ID: 20635943
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Antibody-based therapeutics to watch in 2011.
    Reichert JM
    MAbs; 2011; 3(1):76-99. PubMed ID: 21051951
    [TBL] [Abstract][Full Text] [Related]  

  • 55. 7th annual European Antibody Congress 2011: November 29-December 1, 2011, Geneva, Switzerland.
    Lugovskoy AA; Reichert JM; Beck A
    MAbs; 2012; 4(2):134-52. PubMed ID: 22453093
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion study.
    Meric-Bernstam F; Beeram M; Hamilton E; Oh DY; Hanna DL; Kang YK; Elimova E; Chaves J; Goodwin R; Lee J; Nabell L; Rha SY; Mayordomo J; El-Khoueiry A; Pant S; Raghav K; Kim JW; Patnaik A; Gray T; Davies R; Ozog MA; Woolery J; Lee KW
    Lancet Oncol; 2022 Dec; 23(12):1558-1570. PubMed ID: 36400106
    [TBL] [Abstract][Full Text] [Related]  

  • 57. "NextGen" Biologics: Bispecific Antibodies and Emerging Clinical Results.
    Thakur A; Lum LG
    Expert Opin Biol Ther; 2016; 16(5):675-88. PubMed ID: 26848610
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Editorial: Global Regulatory Initiatives Deliver Accelerated Approval of the First Bispecific Therapeutic Monoclonal Antibody for Advanced Non-Small Cell Lung Cancer (NSCLC).
    Parums DV
    Med Sci Monit; 2021 Sep; 27():e934854. PubMed ID: 34565792
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Bispecific antibodies for the treatment of lymphomas: Promises and challenges.
    Schuster SJ
    Hematol Oncol; 2021 Jun; 39 Suppl 1():113-116. PubMed ID: 34105818
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Generation of bispecific antibodies using chemical conjugation methods.
    Dimasi N; Kumar A; Gao C
    Drug Discov Today Technol; 2021 Dec; 40():13-24. PubMed ID: 34916015
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.